Journals / Turkish Journal of Medical Sciences / 2020 / Cilt: 50 - Sayı: 8

Survival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer

Pages
1838–1850
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Background/aim: This study aimed to investigate the effect of clinical and pathological indicators at the time of the diagnosis on overall survival in patients recently diagnosed with non-small cell lung cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: This study aimed to investigate the effect of clinical and pathological indicators at the time of the diagnosis on overall survival in patients recently diagnosed with non-small cell lung cancer.
📊
Key Findings & Data:Materials and methods: The study population consisted of patients who were diagnosed at the Faculty of Medicine at Isparta Süleyman Demirel University Hospital between January 1, 2010 and December 31, 2017 and presented to the medical oncology outpatient clinic.
💡
Conclusion & Impact:Conclusions: In this study, sex, stage, performance status, the presence of liver or bone metastases, and treatment had an effect on overall survival.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Background/aim: This study aimed to investigate the effect of clinical and pathological indicators at the time of the diagnosis on overall survival in patients recently diagnosed with non-small cell lung cancer. Materials and methods: The study population consisted of patients who were diagnosed at the Faculty of Medicine at Isparta Süleyman Demirel University Hospital between January 1, 2010 and December 31, 2017 and presented to the medical oncology outpatient clinic. Results: A total of 518 patients were evaluated, including 260 patients with squamous cell carcinoma, 207 patients with adenocarcinoma, 50 patients with non-small cell lung cancer-not otherwise specified, and 1 patient with large cell carcinoma. The average life expectancy was found to be 11.50 ± 1.40 months in patients with squamous cell carcinoma, 12.60 ± 1.59 months in patients with adenocarcinoma, and 8.70 ± 1.87 months in the other patients. The estimated 5-year relative survival rate for non-small cell lung cancer was 8% (7% for men and 18% for women). In the multivariate analysis, sex being male (HR, 2.41; P 2 (HR, 1.70; P < 0.001), the stage of cancer (HR, 1.37; P = 0.045), the presence of bone or liver metastasis (HR, 1.44, P = 0.009, HR, 1.57; P = 0.016, respectively), and the patient not having received radiotherapy (HR, 3.25; P < 0.001) or chemotherapy (HR, 1.85; P = 0.001) were defined as statistically significant predictive factors that reduced the overall survival. Conclusions: In this study, sex, stage, performance status, the presence of liver or bone metastases, and treatment had an effect on overall survival.

🔖

Cite This Article

KOÇER, M., ÖNAL, Ö., EROĞLU, H. N., YILMAZ, S. D., KARADOĞAN, D., EROĞLU, İ. (2022). Survival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 8, 1838–1850. https://ajindex.com/articles/609693

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer Journal for Clinicians 2018; 68 (6): 394- 424. doi: 10.3322/caac.21492 2. Gültekin M, Boztaş G. Türkiye kanser istatistikleri. Ministry of Health, Public Health Agency of Turkey; 2014; 43. 3. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005; 128 (1): 452-462. doi: 10.1378/chest.128.1.452 4. Howlader N, Noone AM, Krapcho M, Miller D, Brest A et al. SEER cancer statistics review, 1975-2015. National Cancer Institute; 2015. 5. Fu XL, Zhu XZ, Shi DR, Xiu LZ, Wang LJ et al. Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 1999; 23(2): 143-152. doi: 10.1016/s0169- 5002(99)00009-4 6. Gazdar AF, Schiller JH. Predictive and Prognostic Factors for Non–Small Cell Lung Cancer Potholes in the Road to the Promised Land. Journal of the National Cancer Institute 2011; 103 (24): 1810-1811. doi: 10.1093/jnci/djr497 7. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982; 5(6): 649-656. doi: 10.1097/00000421-198212000-00014 8. Rami‐Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Cancer Journal for Clinicians 2017; 67 (2): 138-155. doi: 10.3322/caac.21390 9. Wang T, Nelson RA, Bogardus A, Grannis Jr FW. Five-year lung cancer survival. Cancer 2010; 116 (6): 1518-1525. doi: 10.1002/ cncr.24871 10. Yang P. Epidemiology of lung cancer prognosis: quantity and quality of life. Methods in Moleculer Biology 2009; 471: 469-486. doi: 10.1007/978-1-59745-416-2_24 11. Radzikowska E, Roszkowski K, Głaz P. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Annals of Oncology. 2002; 13 (7): 1087-1093. doi: 10.1093/ annonc/mdf187 12. Hespanhol V, Queiroga H, Magalhaes A, Santos A, Coelho M et al. Survival predictors in advanced non-small cell lung cancer.Lung Cancer 1995; 13 (3): 253-267. doi: 10.1016/0169- 5002(95)00497-1 13. Campobasso O, Invernizzi B, Musso M, Berrino FJ. Survival rates of lung cancer according to histological type.British Journ